Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sai Parenteral's's Enterprise Value is ₹27,006 Mil.
Sai Parenteral's's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was ₹201 Mil. Therefore, Sai Parenteral's's EV-to-EBIT ratio for today is 134.19.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Sai Parenteral's's Enterprise Value is ₹27,006 Mil.
Sai Parenteral's's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was ₹347 Mil. Therefore, Sai Parenteral's's EV-to-EBITDA ratio for today is 77.74.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Sai Parenteral's's Enterprise Value is ₹27,006 Mil.
Sai Parenteral's's Revenue for the trailing twelve months (TTM) ended in Sep. 2025 was ₹3,025 Mil. Therefore, Sai Parenteral's's EV-to-Revenue ratio for today is 8.93.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Sai Parenteral's (NSE:SAIPARENT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Sai Parenteral's's current Enterprise Value is ₹27,006 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sai Parenteral's's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was ₹201 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Sai Parenteral's's current Enterprise Value is ₹27,006 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sai Parenteral's's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was ₹347 Mil.
Sai Parenteral's's current Enterprise Value is ₹27,006 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sai Parenteral's's Revenue for the trailing twelve months (TTM) ended in Sep. 2025 was ₹3,025 Mil.
Sai Parenteral's's current Enterprise Value is ₹27,006 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sai Parenteral's's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2025 was ₹-660 Mil.
Sai Parenteral's's current Enterprise Value is ₹27,006 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sai Parenteral's's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was ₹-694 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's Enterprise Value Related Terms
Sai Parenteral's Enterprise Value Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's Enterprise Value Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
Enterprise Value
0.00
0.00
0.00
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Enterprise Value
0.00
0.00
0.00
0.00
NSE:SAIPARENT vs LLY, JNJ, ABBV: Enterprise Value Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Sai Parenteral's's Enterprise Value for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's (NSE:SAIPARENT) has a Enterprise Value of ₹27,006 Mil as of Aug. 09, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Sai Parenteral's and its competitors.
Is Sai Parenteral's' Enterprise Value too high?
Sai Parenteral's' current Enterprise Value is ₹27,006 Mil. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Enterprise Value compare to LLY and JNJ?
Sai Parenteral's' Enterprise Value of ₹27,006 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Sai Parenteral's and its competitors. Sai Parenteral's's current Enterprise Value is ₹27,006 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Enterprise Value of ₹27,006 Mil. The current Enterprise Value is ₹27,006 Mil. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Enterprise Value is ₹27,006 Mil as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
